The stock plunged 11 per cent to Rs 869.50 on the BSE.
At the NSE, it dipped 10 per cent to Rs 869.10.
The stock was the biggest loser among the Sensex and Nifty scrips.
"For Q4 FY15, Sun Pharmaceuticals posted numbers lower-than-expected," said Sarabjit Kour Nangra, VP Research - Pharma of Angel Broking.
Sun Pharmaceutical Industries on Friday posted a consolidated net profit of Rs 888.05 crore for the fourth quarter ended March 31, mainly due to Ranbaxy merger impact and price erosion in some products in the US.
Net profit was adversely impacted by professional charges, harmonisation of policies of erstwhile Ranbaxy with the company, Sun Pharma said in a statement.
"The impact of these items appearing above Earnings Before Interest, Taxes, Depreciation and Amortisation (EBITDA) was approximately 10 per cent of net sales and on items appearing below EBITDA was around 7 per cent of net sales," it said.
The financials for fourth quarter of 2014-15 and full year include the impact of the merger of Ranbaxy into Sun Pharma, and hence are not strictly comparable with the same period last year, the company had said.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
